Myriad Genetics

MYGN

Market cap $654M

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until mid-to-late 2026.

Myriad Genetics (MYGN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.

Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Myriad Genetics, Inc. ( MYGN ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Mark Verratti - Chief Operating Officer Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lauren Timmins - Jefferies LLC, Research Division Ricki Levitus - Guggenheim Securities, LLC, Research Division Lu Li - UBS Investment Bank, Research Division Benjamin Mee - Stephens Inc., Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics' Third Quarter 2025 Earnings Conference Call.

Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expectations . Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.

Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company's quarterly earnings will be released the same day after the market closes.

The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations